Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Keytruda Boon Aside, MSD Japan Mulls Job Cuts for Sales and Marketing
US Merck is considering shedding jobs in Japan, apparently targeting sales and marketing staffers this time, despite the phenomenal growth it is enjoying with its immuno-oncology star Keytruda (pembrolizumab), informed sources told Jiho on September 3. According to the sources,…
To read the full story
Related Article
- Labor Union Urges MSD Japan to Make Convincing Case on Job Cuts
September 6, 2019
- MSD Japan Chief Flags Re-Pricing for Keytruda, Says It’s “Heading into That Range”
April 22, 2019
- MSD to Cut 250 Jobs as It Foresees Portfolio Changes
August 31, 2017
BUSINESS
- Chiba Downpours Cause No Major Disruption to Drug Operations
August 17, 2026
- Chugai Files Tecentriq for Colon Cancer Adjuvant Therapy in Japan
August 17, 2026
- Enflonsia Filed for High-Risk Children in 2nd RSV Season in Japan: MSD
August 17, 2026
- Keytruda Keeps Grip on Top Spot in July Drug Sales: Encise
August 17, 2026
- Japan Ethical Drug Sales Jump 9% in June: Crecon
August 17, 2026
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…